Onyx Scientific, Cancer Research U.K. partner
Cancer Research U.K. is using Onyx Scientific, a U.K. CRO, to manage several of its drug development projects in a bid to maximize value.
Onyx Scientific now is supporting Cancer Research U.K. across a portfolio of drug substance campaigns, covering the development and manufacturing of API for use in clinical trials. Cancer Research U.K.'s drug development office is utilizing the contract manufacturing organization’s (CMO) experience in process development, solid-state chemistry, analytical and GMP synthesis of API for use in phase I clinical trials.
Cancer Research U.K. initially selected the chemistry specialist for a GMP synthesis project in 2011. There have been further successful GMP campaigns since that first project.
Dr. Nigel Westwood, drug supply manager at Cancer Research U.K., said, "Over the last few years, the team at Onyx Scientific has worked proactively with us on several challenging synthetic chemistry projects.”
With MHRA and FDA inspected facilities in the U.K. and India, Onyx Scientific assists companies with medicinal chemistry and preclinical development through phase I-III, scaling up to large-scale API production.
The CMO's U.K.-based laboratories deal with challenging chemistry to deliver early stage programs and then are able to scale up, tech transfer and increase project efficiency using the parent company's commercial manufacturing sites in India.